FROM OUR EXPERTS
Generic Name: SITAGLIPTIN/SIMVASTATIN - ORAL Pronounced: (SYE-ta-GLIP-tin/SIM-va-STAT-in) sitagliptin-simvastatin Oral Precautions
Before taking this product, tell your doctor or pharmacist
if you are allergic to sitagliptin or simvastatin; or if you have any other
allergies. This product may contain inactive ingredients, which can cause
allergic reactions or other problems. Talk to your pharmacist for more
Before using this medication, tell your doctor or
pharmacist your medical history, especially of:
disease of the pancreas (pancreatitis)
You may experience blurred vision, dizziness, or
drowsiness due to extremely low or high blood sugar levels. Do not drive, use
machinery, or do any activity that requires alertness or clear vision until you
are sure you can perform such activities safely.
Before having surgery, tell your doctor or dentist about
all the p...
"This is a pretty clear failure. Physicians should now stop using ezetimibe or Vytorin except as a last resort." - Dr. Steven Nissen (Cleveland Clinic, OH) "Dr. Nissen's suggestion about a moratorium on ezitimibe is rather alarmist, given that this was just an imaging study, and an imaging study should not change clinical practice." - Dr. Robert Harrington (Duke Clinical Research Institute, Durham, NC) These 2 quotes pertain to the January 14th release of the ENHANCE study, a trial that evaluated the effects of ezetimibe + simvastatin (aka Vytorin ) on preventing neck artery thickness. As you can tell, the announcement by the manufacturers Merck and Schering-Plough was disappointingly negative and has generated significant controversy. Talk about timing. I just wrote my last article in early January on ezetimibe and how the liver safety of this medication when used in combination with a statin was called into question. One reaso...
Several days, ago, it was discussed in the New Jersey Star-Ledger. Then the New York Times. So I guess it's my turn. The New Jersey paper frequently reports and editorializes on drug company problems. No big surprise, as many drug companies are in NJ -- including Schering-Plough and Merck, who have had a recent egg-on-their-face episode with delayed reporting of a study involving Vytorin and Zetia. But then the New York Times chimed in the next day (April 2) with an editorial, Overpromoted Cholesterol Drugs . The Times editorialized that "It is distressingly late to be learning that these drugs may provide little or no benefit." Time to clear up the air... sorry, NY Times, but they do have benefit, although a small study came to inconclusive results about their effects on some biomarkers. Seems that Schering Plough and Merck have been co-marketing a combination drug for hyperlipidemia, called Vytorin. Vytorin is a combination of two ingredients: Zetia (ezetimibe) and Zocor (...
You should know
Answers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.